蒽环类药物诱导的心脏毒性——我们是否即将跨越这一障碍?
蒽环类药物显著改善多种恶性肿瘤的总生存,但可导致急性和慢性心脏毒性,长期心脏毒性可致约三分之一患者死亡。活性氧和拓扑异构酶IIβ抑制被认为是关键机制。预防策略包括血管紧张素转换酶抑制剂、沙坦类、β受体阻滞剂、醛固酮拮抗剂、他汀类药物、铁螯合剂及开发新型蒽环类衍生物。本综述讨论临床评估过的多柔比星类似物及新型脂质体蒽环类药物L-Annamycin用于软组织肉瘤肺转移和急性髓系白血病的最新进展。
要点
- 蒽环类是最有效的细胞抑制药物之一,但急性和慢性心脏毒性是重要挑战。
- 活性氧和拓扑异构酶IIβ抑制被认为是蒽环类心脏毒性的关键机制。
- 预防策略包括ACEI、沙坦类、β受体阻滞剂、醛固酮拮抗剂、他汀类、铁螯合剂及新型衍生物。
核心结论
- 蒽环类药物治疗相关心脏毒性是亟待解决的临床问题,目前正通过药物预防和开发低心脏毒性衍生物等策略应对。
研究设计与样本
- 综述,讨论临床评估过的多柔比星类似物及新型脂质体蒽环类药物L-Annamycin用于软组织肉瘤肺转移和急性髓系白血病的最新进展。
主要发现
- 长期心脏毒性可导致约三分之一患者死亡。
- 活性氧(源于蒽环类细胞内代谢)和药物诱导的拓扑异构酶IIβ抑制被认为是心脏毒性的关键机制,但部分分子通路机制尚未完全阐明。
关键数值与推荐
- 预防策略包括:(i)血管紧张素转换酶抑制剂、沙坦类、β受体阻滞剂、醛固酮拮抗剂和他汀类药物;(ii)铁螯合剂;(iii)开发心脏毒性很小或没有心脏毒性的新型蒽环类衍生物。
- 综述讨论了临床评估过的多柔比星类似物,这些类似物被开发为潜在无心脏毒性的抗癌药。
- 综述纳入了新型脂质体蒽环类药物L-Annamycin用于治疗软组织肉瘤肺转移和急性髓系白血病的最新进展。
临床怎么用
- 原文未据此给出推荐。
局限性
- 部分分子通路机制尚未完全阐明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anthracyclines have contributed significantly to remarkable improvements in overall survival and are regarded as the most effective cytostatic drug for cancer treatment in various malignancies. However, anthracyclines are a significant cause of acute and chronic cardiotoxicity in cancer patients, and long-term cardiotoxicity can lead to death in about one-third of patients. Several molecular pathways have been implicated in the development of anthracycline-induced cardiotoxicity, although the underlying mechanisms of some molecular pathways are not fully elucidated. It is now generally believed that anthracycline-induced reactive oxygen species (resulting from intracellular metabolism of anthracyclines) and drug-induced inhibition of topoisomerase II beta are the key mechanisms responsible for the cardiotoxicity. To prevent cardiotoxicity, several strategies are being followed: (i) angiotensin-converting enzyme inhibitors, sartans, beta-blockers, aldosterone antagonists, and statins; (ii) iron chelators; and (iii) by development of new anthracycline derivatives with little or no cardiotoxicity. This review will discuss clinically evaluated doxorubicin analogues that were developed as potentially non-cardiotoxic anticancer agents and include recent development of a novel liposomal anthracycline (L-Annamycin) for the treatment of soft-tissue sarcoma metastatic to the lung and acute myelogenous leukaemia.
引用
- Dempke WCM, Zielinski R, Winkler C, et al. Anthracycline-induced cardiotoxicity - are we about to clear this hurdle? Eur J Cancer. 2023. PMID: 36966697. doi:10.1016/j.ejca.2023.02.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。